Home > > > > Report Detail

Global and China Stem Cell Industry Report, 2015-2018

Publisher Name :
Date: 25-Nov-2015
No. of pages: 120
Inquire Before Buying

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research.

Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out.

Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia.

Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies.

In February 2015, Ministry of Science and Technology of the People’s Republic of China published the Stem Cell and Translational Medicine Implementation Plan of National Key R&D Program (Draft). In August 2015, CFDA (China Food and Drug Administration) issued Management on Clinical Stem Cell Experimental Study (Trial). With the relaxation of policies, the stem cell industry has attracted Chinese investors once again.

On December 4, 2014, Xi'an International Medical Investment (formerly known as Kaiyuan Investment) announced to invest RMB270 million in acquiring 34% stake in H & B’s registered capital in order to accelerate the development of health care services and foster new profit engines.

On April 17, 2015, Yinhe Investment proclaimed that it would associate with its controlling shareholder Yinhe Group to jointly lavish RMB2 billion in the establishment of Biomedical M&A Fund whose total size hits RMB6 billion. The fund is mainly used for immunotherapy, stem cell clinical application platforms, macromolecular drugs, antibody drug development and other fields.

On October 27, 2015, Ningxia Xinri Hengli Steel Wire Rope Co., Ltd. released a restructuring plan to take over 80% stake in BoyaLife from Xu Xiaochun, Maoxing Investment Management (Hangzhou), Yang Lijuan,Wang Jianrong, etc. with RMB1.5656 billion.

Global and China Stem Cell Industry Report, 2015-2018 highlights the followings:


  • Classification, application, industry chain definition, etc. of stem cells;

  • Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;

  • Policies, upstream/midstream/downstream development, etc. of China stem cell industry;

  • Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide.

Global and China Stem Cell Industry Report, 2015-2018

Table of Contents

1. Overview of Stem Cell Industry
1.1 Definition
1.2 Classification and Application
1.3 Industry Chain
1.4 Development Course

2. Global Stem Cell Industry Chain
2.1 Industry Chain Layout of Major Enterprises
2.2 Policy
2.3 Development
2.4 Upstream
2.5 Downstream
2.6 Prospect

3. China Stem Cell Industry Chain
3.1 Development
3.2 Policy
3.3 Upstream
3.4 Midstream
3.5 Downstream

4. Upstream Enterprises
4.1 Cryo-Cell International
4.1.1 Profile
4.1.2 Operation
4.1.3 Cord Blood Business
4.2 Esperite
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Stem Cell Business
4.3 VCANBIO
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Stem Cell Business
4.3.7 Development Forecast
4.4 Golden Meditech
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Cord Blood Business
4.4.5 Development Forecast
4.5 LifeCell International
4.5.1 Profile
4.5.2 Cord Blood Business
4.6 Cryosite
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Stem Cell Business
4.7 Health & Biotech
4.7.1 Profile
4.7.2 Operation
4.8 Tian Qing Stem Cell
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure

5. Midstream and Downstream Enterprises
5.1 Caladrius Biosciences
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 R&D and Investment  
5.1.5 Stem Cell Business  
5.2 Mesoblast
5.2.1 Profile
5.2.2 Operation
5.2.3 R&D and Investment  
5.2.4 Stem Cell Business  
5.3 MEDIPOST
5.3.1 Profile
5.3.2 Operation
5.3.3 Stem Cell Business  
5.4 Beike Biotechnology
5.4.1 Profile
5.4.2 Stem Cell Business  
5.5 Osiris Therapeutics
5.5.1 Profile
5.5.2 Operation
5.5.3 R&D
5.6 Orthofix International
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 R&D
5.6.5 Stem Cell Business  
5.7 Cytori Therapeutics
5.7.1 Profile
5.7.2 Operation
5.7.3 R&D
5.8 Athersys
5.8.1 Profile
5.8.2 Operation
5.8.3 R&D
5.9 Pluristem Therapeutics
5.9.1 Profile
5.9.2 R&D and Recent News
5.10 StemCells
5.10.1 Profile
5.10.2 Operation
5.10.3 R&D
5.11 Ocata
5.11.1 Profile
5.11.2 Operation
5.11.3 R&D
5.12 Celgene
5.12.1 Profile
5.12.2 Operation
5.12.3 R&D
5.13 Vitro Biopharma
5.13.1 Profile
5.13.2 Operation
5.13.3 R&D
5.13.4 Stem Cell Business  
5.14 Reneuron
5.14.1 Profile
5.14.2 Operation
5.14.3 R&D
5.15 Tigenix
5.15.1 Profile
5.15.2 Operation
5.15.3 R&D
5.16 Cellular Biomedicine
5.16.1 Profile
5.16.2 Operation
5.16.3 R&D
5.16.4 Stem Cell Business  
5.16.5 Business in China
5.17 SALIAI
5.17.1 Profile
5.17.2 Operation
5.17.3 Stem Cell Business  
5.18 Opexa Therapeutics
5.19 ZhongKe Biopharm
5.20 Cyagen Biosciences

List of Charts

Classification of Stem Cell
Overview of Stem Cell Therapy Area (by Disease Type)
Advantages and Disadvantages of Stem Cell Therapy
Source and Application of Adult Stem Cells (by Type)
Stem Cell Industry Chain
Industry Chain Distribution of Major Global Stem Cell Enterprises
Policy Tendency of Human Embryonic Stem Cell Research Worldwide
Stem Cell Products Granted "Orphan Drug" by EU EMEA
Global Authorized Stem Cell Varieties
Top 20 Indications of Global In-research Stem Cell by the end of 2014
Global Stem Cell Products in Late R&D Stage 
Global Stem Cell Market Size and YoY Growth, 2007-2014
Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2014
Distribution of Cord Blood-related Research Projects Registered in the US National Institutes of Health, by Nov 17, 2015
Clinical Application of Global Stem Cell Technology (by Disease Type), 2014
Cord Blood Bank Distribution in Major Countries by the end of 2014
Cord Blood Application in Major Countries
Global Top 10 Death Causes (by Death Toll), 2012
Global Top 10 Death Causes (by Income Group), 2012
Global Top 10 Death Causes in Low-income Countries, 2012
Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
Global Top 10 Death Causes in Middle- and High-income Countries, 2012
Global Top 10 Death Causes in High-income Countries, 2012
Application Prospect of Global Stem Cell
Global Stem Cell Market Size and YoY Growth, 2014-2018E
Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA
Construction of Chinese Stem Cell Industrialization Bases
China's Stem Cell Industry Policies, 1999-2015
Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry
Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry
Chinese Stem Cell Medical Market Size and YoY Growth, 2007-2018E
Revenue and Net Income of Cryo-Cell International, FY2010-FY2015
Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014
Cord Blood Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2015
Revenue and Net Income of Esperite, 2010-2015
Revenue of Esperite (by Business), 2010-2015
Revenue Structure of Esperite (by Region), 2014
Stem Cell Storage of Esperite, 2009-2014
Stem Cell Storage Revenue and EBITA of Esperite, 2010-2015
Operation of Main Subsidiaries of VCANBIO by 2015H1
Revenue and Net Income of VCANBIO, 2010-2015
Revenue of VCANBIO (by Business), 2011-2015
Revenue of VCANBIO (by Region), 2011-2015
Gross Margin of VCANBIO (by Business), 2011-2015
R&D Costs and % of Total Revenue of VCANBIO, 2011-2015
Fund-raising Investment Projects and Progress of VCANBIO, by Jun 30, 2015
Stem Cell Storage Business of VCANBIO (by Type), 2009-2014
Revenue and Net Income of VCANBIO, 2014-2017E
Revenue and Net Income of Golden Meditech, FY2009-FY2014
Revenue of Golden Meditech (by Business), FY2009-FY2014
Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014
Cord Blood Bank Gross Profit and Gross Margin of Golden Meditech, FY2011-FY2014
Development Course of Golden Meditech’s Cord Blood Storage Business
Revenue and Net Income of Golden Meditech, FY2014-FY2018E
Development Course of LifeCell International
Revenue and Net Income of Cryosite, FY2011-FY2015
Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014
Equity Structure of Health & Biotech  
Industry Base Distribution of Health & Biotech
Revenue and Net Income of Health & Biotech, 2012-2014   
Revenue and Net Income of Tian Qing Stem Cell, 2013-2015
Revenue (by Business) of Tian Qing Stem Cell, 2013-2015
Subsidiaries of Caladrius Biosciences, by the end of 2014
Revenue and Net Income of Caladrius Biosciences, 2009-2015
Revenue (by Business) of Caladrius Biosciences, 2012-2015
R&D Costs and % of Total Revenue of Caladrius Biosciences, 2009-2014
M & A Course of Caladrius Biosciences, 2009-2014
Revenue and Net Income of Mesoblast, FY2009-FY2015
R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2015
M&A Course of Mesoblast by the end of 2014
Stem Cell Product R&D Progress of Mesoblast by the end of June 2015
Revenue and Net Income of MEDIPOST, 2011-2014
Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
Development Course of Beike Biotechnology
Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
Revenue, Net Income and Gross Margin of Osiris Therapeutics, 2011-2015
R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2015
Revenue, Net Income and Gross Margin of Orthofix International, 2009-2014
Revenue of Orthofix International (by Department), 2011-2015
R&D Costs and % of Total Revenue of Orthofix International, 2011-2015
Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2010-2015
Revenue of Cytori Therapeutics (by Region), 2010-2015
R&D Costs and % of Total Revenue of Cytori Therapeutics, 2010-2015 Revenue and Net Income of Athersys, 2010-2015
Revenue of Athersys (by Source), 2010-2015
R&D Costs and % of Total Revenue of Athersys, 2010-2015
Significant Cooperative Partners and Areas of Athersys
Revenue and Net Income of StemCells, 2011-2015
R&D Costs and % of Total Revenue of StemCells, 2011-2015
Stem Cell Product R&D, Therapeutic Area and Progress of StemCells by 2015H1
Revenue, Net Income and Gross Margin of Ocata, 2010-2015
R&D Costs and % of Total Revenue of Ocata, 2010-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Ocata by the end of 2014
Revenue, Net Income and Operating Margin of Celgene, 2009-2014
Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
Revenue and Net Income of Vitro Biopharma, FY2009-FY2015
R&D Costs and % of Total Revenue of Vitro Biopharmas, FY2009-FY2015
Stem Cell Brands and Application Fields of Vitro Biopharma
Revenue and Net Income of Reneuron, FY2010-FY2015
R&D Costs and % of Total Revenue of Reneuron, FY2010-FY2015
Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2014
Revenue and Net Income of Tigenix, 2009-2015
Sales of Tigenix (by Region), 2011-2013
R&D Costs and % of Total Revenue of Tigenix, 2012-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Tigenix by 2015H1
Development Course of Cellular Biomedicine
Revenue and Net Income of Cellular Biomedicine, 2013-2015
R&D Costs and % of Total Revenue of Cellular Biomedicine, 2013-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Cellular Biomedicine by 2015H1
Revenue and Net Income of SALIAI, 2013-2015

  • Global Animal Stem Cell Therapy Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 89
    Animal stem cell therapy is a usage of animal's stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involves three steps which include collection of stem cell sample from animals and preparing The sample to concentrate The stem cells. Finally, The therapy includes transferring The stem cells into The injured site ......
  • Global Mesenchymal Stem Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 104
    According to our LPI (LP Information) latest study, the global Mesenchymal Stem Cells market size was valued at US$ 202.6 million in 2023. With growing demand in downstream market, the Mesenchymal Stem Cells is forecast to a readjusted size of US$ 278.8 million by 2030 with a CAGR of 4.7% during review period. The research report highlights the growth potential of the global Mesenchymal Stem Cells market. Mesenchymal Stem Cells are expected to show stable growth in the future market. How......
  • Global Stem Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 151
    According to our LPI (LP Information) latest study, the global Stem Cells market size was valued at US$ 2693.1 million in 2023. With growing demand in downstream market, the Stem Cells is forecast to a readjusted size of US$ 5700.6 million by 2030 with a CAGR of 11.3% during review period. The research report highlights the growth potential of the global Stem Cells market. Stem Cells are expected to show stable growth in the future market. However, product differentiation, reducing costs......
  • Global Stem Cell Therapy Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Stem Cell Therapy market size was valued at US$ 469.1 million in 2023. With growing demand in downstream market, the Stem Cell Therapy is forecast to a readjusted size of US$ 1724 million by 2030 with a CAGR of 20.4% during review period. The research report highlights the growth potential of the global Stem Cell Therapy market. Stem Cell Therapy are expected to show stable growth in the future market. However, product differ......
  • Global Animal Stem Cell Therapy Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 114
    According to our LPI (LP Information) latest study, the global Animal Stem Cell Therapy market size was valued at US$ 199.3 million in 2023. With growing demand in downstream market, the Animal Stem Cell Therapy is forecast to a readjusted size of US$ 476.2 million by 2030 with a CAGR of 13.2% during review period. The research report highlights the growth potential of the global Animal Stem Cell Therapy market. Animal Stem Cell Therapy are expected to show stable growth in the future ma......
  • Global Stem Cell Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Stem Cell market: According to our latest research, the global Stem Cell market looks promising in the next 5 years. As of 2022, the global Stem Cell market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Stem cells are cells that can differentiate into other types of cells, and can also divide in self-renewal to produce more of the same type of stem cells. ......
  • Global Animal Stem Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 112
    According to our (Global Info Research) latest study, the global Animal Stem Cell Therapy market size was valued at USD 209.7 million in 2023 and is forecast to a readjusted size of USD 469.9 million by 2030 with a CAGR of 12.2% during review period. Animal stem cell therapy is a usage of animal's stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or di......
  • Global Hematopoietic Stem Cells Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 114
    Market Overview of Global Hematopoietic Stem Cells market: According to our latest research, the global Hematopoietic Stem Cells market looks promising in the next 5 years. As of 2022, the global Hematopoietic Stem Cells market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global......
  • Global Adipose Stem Cells (ASCS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 122
    Market Overview of Global Adipose Stem Cells (ASCS) market: According to our latest research, the global Adipose Stem Cells (ASCS) market looks promising in the next 5 years. As of 2022, the global Adipose Stem Cells (ASCS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the glo......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs